IDEX (IEX) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
5 Mar, 2026Strategic positioning and business model
Focuses on mission-critical engineered products, targeting higher-growth, specialized markets with proprietary technologies across diverse sectors.
Operates with an 8020 model emphasizing simplification, agility, and autonomy, supporting global brands in over 100 countries.
Maintains an asset-light manufacturing approach, leveraging proprietary and co-developed technologies for high-margin, specialized applications.
Continuously evolves its portfolio toward markets with secular growth trends, supported by disciplined capital allocation and M&A activity.
Prioritizes organic growth, strategic acquisitions, and double-digit EPS growth over the long term.
Segment performance and market focus
Health & Science Technologies led 2024 sales (39%), followed by Fluid & Metering Technologies (38%) and Fire & Safety/Diversified Products (23%).
Health & Science Technologies targets life sciences, semiconductors, and analytical instruments, with a 5% CAGR and 31% EBITDA margin in 2024.
Fluid & Metering Technologies serves industrial, water, energy, and agriculture markets, achieving a 7% CAGR and 33% EBITDA margin in 2024.
Fire & Safety/Diversified Products focuses on fire suppression, rescue tools, and dispensing, with a 5% CAGR and 29% EBITDA margin in 2024.
Strategic acquisitions in data centers, semiconductors, water, and defense enhance capabilities and market reach.
Financial performance and capital allocation
2024 revenue reached $3.3B, with adjusted EBITDA of $874M and free cash flow of $603M.
Achieved 5.6% five-year revenue CAGR and 6.3% five-year adjusted EPS CAGR, despite recent market contractions in life sciences and semiconductors.
Maintains a gross leverage ratio below 2.0x, with a track record of rapid deleveraging post-acquisitions.
Targets 100%+ free cash flow conversion and consistent dividend payouts (30–35% of adjusted net income).
Increased share repurchase authorization to $1 billion as of September 2025.
Latest events from IDEX
- Midpoint of phase three: HST drives growth, digital and AI adoption accelerate, M&A continues.IEX
Citi's Global Industrial Tech & Mobility Conference 202617 Feb 2026 - Record HST-driven growth and margin gains support 2026 outlook amid industrial headwinds.IEX
Q4 20254 Feb 2026 - $1B acquisition expands tech capabilities and market reach, with strong synergy and margin upside.IEX
M&A Announcement3 Feb 2026 - Q2 sales fell 5%, margins and EPS improved, guidance cut, and $1B Mott deal announced.IEX
Q2 20242 Feb 2026 - Q3 sales up 1%, adjusted EPS down 10%, Mott deal closed, and guidance steady amid macro risks.IEX
Q3 202417 Jan 2026 - Record Q4 sales and margin gains set up 2025 for organic growth and EPS expansion.IEX
Q4 20249 Jan 2026 - Record orders and resilient margins offset organic sales and EPS declines in Q1.IEX
Q1 202525 Dec 2025 - Board recommends all proposals except the shareholder hiring report, emphasizing governance and ESG.IEX
Proxy Filing15 Dec 2025 - Key votes include director elections, auditor ratification, and a proposal on inclusive hiring.IEX
Proxy Filing1 Dec 2025